Supporting Information

Novel Peptoid Building Blocks: Synthesis of Functionalized Aromatic Helix-Inducing Submonomers

Jiwon Seo, [†] Annelise E. Barron, [†] and Ronald N. Zuckermann ^{‡,*}

[†]Department of Bioengineering, Stanford University, W300 James H. Clark Center, 318 Campus

Drive, Stanford, CA 94305-5440, USA.

[‡]Biological Nanostructures Facility, The Molecular Foundry, Lawrence Berkeley National Laboratory,

1 Cyclotron Rd., Berkeley, CA 94720, USA.

Email: rnzuckermann@lbl.gov

Table of Contents

1. General methods	S2
2. Synthesis of submonomers 6, 11, and 12	S4
3. Synthesis of guanidine-functionalized submonomer S13-5	S13
4. Sidechain cleavage in strong acidic conditions	S16
5. Synthesis of peptoid 20	S17
6. Synthesis of homodimeric peptoid helix bundle 21	S20
7. HPLC and ESI-MS data of Peptoids 13-19	S22
8. ¹ H and ¹³ C NMR spectra	S25

1. General Methods.

Biotage SP1TM purification system and flash cartridges were used for flash column chromatography. Thin-layer chromatography was carried out on precoated aluminum-backed TLC sheets (silica gel 60 F_{254} , EMD chemicals, San Diego, CA). Compounds were visualized with a ninhydrin spray reagent or a UV/vis lamp. ¹H and ¹³C NMR spectra were recorded on a Bruker 500 MHz NMR spectrometer. Chemical shifts were reported as δ values in parts per million downfield from TMS (δ 0.0) as the internal standard in CDCl₃. All reagents were purchased from Sigmaaldrich, Fisher and Novabiochem. They were used without further purification unless stated otherwise. (*R*)-(+)-*tert*-Butanesulfinamide was purchased from Advanced Asymmetrics, Inc., IL, USA. (*S*)- α -Methyl-4-nitrobenzylamine hydrochloride was purchased from TCI America, OR, USA. *N*,*N**-Diisopropylcarbodiimide was purchased from Advanced ChemTech, KY, USA.

The peptoid oligomers were synthesized by solid-phase submonomer method on solid support using an automated synthesis (Aapptec Apex 396 parallel synthesizer, Louisville, KY, USA) or a manual synthesis. Rink amide resin (0.60 mmol/g, Novabiochem, San Diego, CA, USA) was used to generate C-terminal amide peptoids. After Fmoc deprotection, each monomer was added by a series of bromoacetylation and displacement by a primary amine. These two steps were iterated with appropriate primary amines until desired peptoid sequence was obtained. Typically, 0.06 mmol reaction scale was used (0.1 g of the resin). For bromoacetylation, the addition of bromoacetic acid (1 mL, 1.2 M in DMF, 1.2 mmol) followed by *N*,*N*'-diisopropylcarbodiimide (0.15 mL, neat, 1.0 mmol), and then agitation at room temperature for 20 min were performed. For the displacement reaction, primary amine (1 mL, 1.2 M in NMP or *N*-methylpyrrolidone) was added, and the reactor was agitated at room temperature for 1 h. The resin was washed with DMF (6 mL × 5) between each step. *N*-Terminal acetylation was performed manually by adding acetic anhydride (0.12 mL, 1.3 mmol) and pyridine (0.13 mL, 1.6 mmol) to the resin-bound peptoid in DMF (1 mL). The reaction was continued at room temperature for 2 hours. Peptoid 20 was cleaved from the resin with 42.5:50:5:2.5 TFA/CH₂Cl₂/water/triisopropylsilane (v/v/v/v) for 5 minutes at room temperature. Other peptoids

were cleaved with 95:2.5:2.5 TFA/water/triisopropylsilane (v/v/v) for 10 - 20 minutes at room temperature (i.e. longer TFA treatment was applied for *tert*-butyl ester deprotection). The cleavage solution was filtered by solid-phase extraction (SPE) cartridges (Applied Separations, Allentown, PA, USA) and the volatiles were removed by a stream of nitrogen. The crude peptoid was dissolved in acetonitrile and analyzed by ESI, Maldi-TOF, and analytical HPLC.

LC-MS data were obtained using an Agilent Technologies 1100 Series and LC/MSD Trap XCT system (Agilent Technologies, Santa Clara, CA, USA). Vydac C4 column was used with mobile phase of water (0.1% TFA) and acetonitrile (0.1% TFA). The Maldi-TOF mass spectra were obtained by an Applied Biosystems 4800 MALDI TOF/TOF Analyzer system (Applied Biosystems, Foster City, CA, USA). α -Cyano-4-hydroxycinnamic acid (5 mg/mL in CH₃CN/H₂O = 1:1 with 0.1% TFA) was used as the matrix. Analytical HPLC was performed on a Varian modular HPLC system (ProStar 210 solvent delivery system, ProStar 325 UV-Vis dual wavelength detector, autosampler model 430, and column oven model510). Sample purity was monitored by absorbance at 220 nm. Grace Vydac protein & peptide C18 column (cat #: 218TP5415) was used for the analytical HPLC. The peptoids were purified by preparative HPLC system (Varian ProStar 210 solvent delivery system, ProStar 345 UV-Vis detector, fraction collector model 210) using a C18 column [Varian Dynamax, 250×21.4 mm, Omnispher 5] at a flow rate of 10 mL/min. Sample elution was detected by absorbance at 220 nm. The mobile phase was used as follows: (A, water + 0.1% TFA; B, CH₃CN + 0.1% TFA) 5 min using 5% B, then a gradient to 99% B over 35 min, 5 min using 99% B, and then a gradient to 5% B over 5 min. For peptoid 20 - 22, acetonitrile and water were degassed and TFA was added. The purity of the product fractions were confirmed by analytical HPLC, and fractions containing pure product were collected, lyophilized, and stored at -80 °C.

Circular dichroism measurements were carried out at 25 °C with a Jasco J-815 circular dichroism spectrometer (Jasco, Inc., Easton, MD, USA). CD spectra were obtained in an 1 mm pathlength quartz cell and recorded from 190 to 260 nm in 1 nm increments with a scanning speed of 20 nm/min and a response time of 4 second. Three scans for each sample were averaged. Stock

solutions of peptoids (1 - 5 mM in acetonitrile) were used, and appropriate dilutions were made immediately before the measurements. Sample concentrations were in the range of 46 - 50 μ M. Data are expressed in terms of per-residue molar ellipticity (deg cm²/dmol) calculated per number of amides in a molecule.

2. Synthesis of Submonomers 6, 11, and 12.

(*R*, *E*)-*N*-[4-(methylthio)benzylidene]-*tert*-butanesulfinamide (2). To a mixture of (*R*)-(+)-*tert*-butanesulfinamide (1, 500 mg, 4.12 mmol) and 4-(methylthio)benzaldehyde (691 mg, 4.54 mmol) in dry THF (10 mL) under nitrogen was added Ti(OEt)₄ (2.07 g, 9.07 mmol) dropwise. After stirring for overnight, the reaction mixture was poured into brine (10 mL). The resulting white suspension was filtered through Celite, and the filter cake was washed twice with EtOAc (10 mL). The filtrate was transferred to a separatory funnel where the organic layer was washed with brine. The aqueous solution was extracted twice with EtOAc (20 mL), and the combined organic solution was dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was recrystallized in EtOAc/hexane to afford 2 (989 mg, 94%) as a white solid. R_f = 0.2 (hexane/EtOAc = 10 : 1); ¹H NMR (500 MHz, CDCl₃) δ 8.52 (s, 1H), 7.75 (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 2.52 (s, 3H), 1.25 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 161.9, 145.0, 130.7, 129.6, 125.6, 57.8, 22.6, 14.9.

(R_s , S)-N-{1-[4-(methylthio)phenyl]ethyl}-tert-butanesulfinamide (3). To a solution of 2 (0.32 g, 1.25 mmol) in dry CH_2Cl_2 (7 mL) was slowly added methylmagnesium bromide (3.0 M in ether, 0.83 mL) at -78 °C. The mixture was stirred at -78 °C for 1 h under nitrogen and then allowed to warm to room temperature and stirred for additional 1 h. The reaction was quenched by slowly adding saturated NH_4Cl aqueous solution (3 mL) at 0 °C, and the aqueous layer was extracted twice with

EtOAc (10 mL). The combined organic solution was dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was recrystallized in EtOAc/hexane to afford **3** (323 mg, 95%) as a white needle-shaped solid. $R_f = 0.1$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.24 (m, 4H), 4.53 (q, J = 3.5 Hz, 1H), 3.29 (d, J = 3.0 Hz, 1H), 2.48 (s, 3H), 1.51 (d, J = 7.0 Hz, 3H), 1.19 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 140.3, 137.6, 127.5, 126.6, 55.5, 54.2, 25.1, 22.6, 15.8; MS (ESI, CH₃CN) [M+H⁺] = 271.5.

$$H_2N$$
 HCI SMe

(S)-1-[4-(methylthio)phenyl]ethylamine hydrochloride (3-S1). To a solution of 3 (1.03 g, 3.79 mmol) in MeOH (1 mL) was slowly added 4 M HCl in 1,4-dioxane solution (7 mL) at 0 °C. The mixture was stirred at room temperature for 45 min. The volume of the reaction mixture was reduced by evaporation, and diethyl ether was added to precipitate the product. The white precipitate was then filtered and washed with ether (10 mL) three times to provide 3-S1 (770 mg, 99%) as a white crystalline solid. $R_f = 0.2$ (EtOAc/MeOH = 1 : 1); ¹H NMR (500 MHz, D₂O) δ 7.37 (m, 4H), 4.49 (q, J = 7.0 Hz, 1H), 2.47 (s, 3H), 1.60 (d, J = 7.0 Hz, 3H).

(*S*)-*N*-{1-[4-(methylthio)phenyl]ethyl}trifluoroacetamide (4). To a solution of 3-S1 (0.57 g, 3.41 mmol) in anhydrous CH₂Cl₂ (20 mL) was added ethyl trifluoroacetate (1.45 g, 10.2 mmol) followed by triethylamine (1.03 g, 10.2 mmol). The reaction mixture was stirred for 16 h under nitrogen and concentrated under reduced pressure. The residue was dissolved in EtOAc (30 mL), washed three times with brine (15 mL), and dried over Na₂SO₄. After evaporation of the organic solvent, the residue was recrystallized in hot hexane/CH₂Cl₂ solution to provide 4 (0.77 g, 86%) as a white needle-shaped solid. $R_f = 0.3$ (hexane/EtOAc = 10 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.23 (m, 4H), 6.35 (s, 1H), 5.09 (m, 1H), 2.46 (s, 3H), 1.56 (d, J = 6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.4, 138.8,

137.6, 127.0, 126.7, 116.9, 49.4, 20.9, 15.7.

(*S*)-*N*-{1-[4-(methylsulfinyl)phenyl]ethyl}trifluoroacetamide (4-S1). Compound 4 (5.15 g, 19.6 mmol) was dissolved in CH₃CN (99.8% anhydrous, Aldrich, 20 mL) and THF (99.9% anhydrous, Aldrich, 40 mL), and to this solution was added Selectfluor (F-TEDA•BF₄, 7.62 g, 21.5 mmol) in CH₃CN (99.8% anhydrous, Aldrich, 10 mL) and H₂O (miliQ, 6 mL) dropwise at 0 °C. After a stirring time of 30 minutes at room temperature, the mixture was concentrated and redissolved in a mixture of EtOAc (50 mL) and 5% aqueous NaHCO₃ (50 mL). The organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was dried under high vacuum pump overnight, and the resulting white solid was recrystallized in hot hexane/EtOAc solution to provide 4-S1 (5.18 g, 95%). *Caution*. This reaction was successful only when the highly pure solvents were used. $R_f = 0.4$ (EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 8.15 and 8.16 (2 × s, 1H), 7.41 – 7.50 (m, 4H), 5.13 (m, 1H), 2.64 and 2.65 (2 × s, 3H), 1.53 – 1.55 (m, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.6, 145.1, 145.0, 144.7, 127.4, 127.3, 124.1, 124.0, 117.1, 49.2, 49.2, 43.7, 21.1, 20.9; MS (ESI, CH₃CN) [M+H⁺] = 279.5. The NMR data showed the presence of sulfoxide diastereomers.

(S)-N-{1-[4-(tritylthio)phenyl]ethyl}trifluoroacetamide (5). A solution of sulfoxide 4-S1 (4.33 g, 15.5 mmol) and 2,6-lutidine (5.15 g, 48.1 mmol) in freshly distilled THF (150 mL) was cooled to -78 °C. To this solution was added trifluoroacetic anhydride (9.77 g, 46.5 mmol) dropwise, and the stirring continued for 1.5 h at -78 °C under nitrogen. After evaporation of volatile components in the reaction mixture, a precooled mixture (0 °C) of triethylamine (25 mL) and methanol (25 mL) was added to the residue. The solution was allowed to warm to room temperature, stirred for 40 min, and then concentrated under reduced pressure. The residue was dissolved in CH₂Cl₂ (100 mL) and

extracted with saturated NH₄Cl (100 mL). The organic layer was separated, dried under Na₂SO₄, and concentrated to dryness giving an oily residue. Thin layer chromatography showed the free thiol spot as $R_f = 0.3$ (hexane/EtOAc = 3 : 1). Without purification, the aromatic thiol was dissolved in freshly distilled CH₂Cl₂ (150 mL), and to this solution was added trityl chloride (8.64 g, 31.0 mmol) and pyridine (2.45 g, 31.0 mmol). The reaction mixture was stirred for 2 days at room temperature under nitrogen, and washed successively with water (100 mL), 5% NaHCO₃ (100 mL), and brine (2 x 100 mL), and dried over Na₂SO₄. The solution was concentrated in vacuo until white solid precipitated out, and the precipitate was filtered. The crude solid product was recrystallized in hot CH₂Cl₂ three times to provide **5** (5.64 g, 74%) as a white solid. $R_f = 0.6$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.42 – 7.44 (m, 6H), 7.21 – 7.27 (m, 9H), 6.96 – 6.97 (m, 4H), 6.33 (d, J = 5.5 Hz, 1H), 5.04 (m, 1H), 1.50 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.0, 144.4, 140.2, 134.9, 134.7, 130.0, 127.7, 126.8, 125.8, 116.9, 71.0, 49.3, 20.9; MS (ESI, CH₃CN) [M+Na⁺] = 513.7.

(*S*)-1-[4-(tritylthio)phenyl]ethylamine (6). To a stirred ice-cold solution of **5** (3.68 g, 7.49 mmol) in MeOH (20 mL) and THF (30 mL) under nitrogen was added 2.0 M aq. LiOH (30 mL) dropwise, and the mixture was stirred at room temperature for 3 h. After evaporation of organic solvents under reduced pressure, the aqueous solution was extracted three times with EtOAc (70 mL). The organic extract was washed with brine, dried over Na₂SO₄, filtered, and evaporated. A yellowish solid was obtained (2.94 g, 99%). $R_f = 0.25$ (EtOAc/MeOH = 1 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.45 – 7.50 (m, 6H), 7.21 – 7.35 (m, 9H), 7.01 – 7.02 (m, 2H), 6.95 – 6.98 (m, 2H), 3.98 – 4.02 (m, 1H), 1.73 (br s, 2H), 1.31 (d, J = 6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 147.6, 144.6, 135.0, 132.4, 130.1, 127.7, 126.7, 125.5, 70.8, 50.9, 25.6; MS (ESI, CH₃CN) [M+Na⁺] = 417.9.

(R, E)-N-(4-cyanobenzylidene)-tert-butanesulfinamide (7). To a mixture of (R)-(+)-tert-

butanesulfinamide (1, 20 g, 165 mmol) and 4-cyanobenzaldehyde (22 g, 167 mmol) in freshly distilled THF (500 mL) under nitrogen was slowly added titanium ethoxide (50 g, 219 mmol). After stirring for overnight, the reaction mixture was poured into brine (500 mL). The resulting white suspension was filtered through Celite, and the filter cake was washed twice with EtOAc (100 mL). The filtrate was transferred to a separatory funnel where the organic layer was washed with brine. The aqueous solution was extracted twice with EtOAc (100 mL), and the combined organic solution was dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was recrystallized in EtOAc/hexane to afford 7 (35 g, 91%) as a white solid. $R_f = 0.35$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 8.60 (s, 1H), 7.93 – 7.95 (m, 2H), 7.75 – 7.77 (m, 2H), 1.26 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 161.1, 137.4, 132.8, 129.6, 118.1, 115.5, 58.4, 22.7.

(R_s , S)-N-[1-(4-cyanophenyl)ethyl]-tert-butanesulfinamide (8). To a solution of 7 (19.8 g, 85 mmol) in dry CH₂Cl₂ (500 mL) was added methylmagnesium bromide (3.0 M in ether, 35 mL) at -78 °C. The mixture was stirred at -78 °C for 1 h under nitrogen and then allowed to warm to room temperature and stirred for additional 1 h. The reaction was quenched by slow addition of saturated NH₄Cl aqueous solution at 0 °C, and the aqueous layer was extracted twice with EtOAc (350 mL). The combined organic solution was dried over Na₂SO₄, filtered, and concentrated in vacuo. Compound 8 was obtained as an oily residue (18.0 g, 85%) and used for the next reaction without further purification. $R_f = 0.25$ (100% EtOAc); ¹H NMR (500 MHz, CDCl₃) δ 7.62 – 7.64 (m, 2H), 7.44 – 7.46 (m, 2H), 4.61 – 4.65 (m, 1H), 3.45 (d, J = 2.5 Hz, 1H), 1.53 (d, J = 7.0 Hz, 3H), 1.21 (s, 9H); ¹³C NMR (125 MHz, CDCl₃) δ 149.1, 132.4, 127.8, 118.7, 111.4, 55.8, 54.3, 24.9, 22.5; MS (ESI, CH₃CN) [M+H⁺] = 250.6.

4-I(S)-1-((R)-tert-butylsulfinamido)ethyl|benzoic acid (9). Compound **8** (5.4 g, 21.5 mmol) was stirred in a mixture of ethylene glycol (70 mL), water (30 mL), and KOH (12.1 g, 215 mmol) for 20 h at 110 °C. The reaction mixture was poured on crushed ice and washed with diethyl ether to remove some impurities. The pH of the aqueous solution was adjusted to 5 by dropwise addition of concentrated aqueous HCl, and the precipitate was filtered. The filtrate was acidified further to pH 4, and the precipitate was filtered. The crude product was collected and recrystallized in hot MeOH/DMSO mixture to provide **9** (4.29 g, 74%) as a yellowish solid. $R_f = 0.35$ (EtOAc/MeOH = 19:1); ¹H NMR (500 MHz, DMSO-*d*6) δ 12.85 (s, 1H), 7.90 (d, J = 7.0 Hz, 2H), 7.46 (d, J = 8.5 Hz, 2H), 5.45 (d, J = 5.0 Hz, 1H), 4.47 (m, 1H), 1.46 (d, J = 7.0 Hz, 3H), 1.11 (s, 9H); ¹³C NMR (125 MHz, DMSO-*d*6) δ 167.6, 150.4, 129.9, 129.8, 127.3, 55.5, 55.2, 25.1, 23.1; MS (ESI, CH₃CN) [M+H⁺] = 269.8.

(*S*)-4-(1-aminoethyl)benzoic acid hydrochloride (10). To an ice-cold solution of 9 (2.0 g, 7.42 mmol) in MeOH (15 mL) was slowly added 4 M HCl in 1,4-dioxane solution (40 mL). The mixture was stirred at room temperature for 40 min. The volume of the reaction mixture was reduced by evaporation, and diethyl ether was added to precipitate the product. The white precipitate was then filtered and washed thoroughly with ether (50 mL) three times to provide 10 (1.48 g, 99%) as a white solid. $R_f = 0.15$ (EtOAc/MeOH = 1 : 1); ¹H NMR (500 MHz, D₂O) δ 8.10 (d, J = 7.0 Hz, 2H), 7.60 (d, J = 7.0 Hz, 2H), 4.65 (q, J = 7.0 Hz, 1H), 1.69 (d, J = 6.5 Hz, 3H); ¹³C NMR (125 MHz, D₂O) δ 168.7, 143.0, 130.4, 130.2, 126.8, 50.7, 19.2.

(S)-4-[1-(benzyloxycarbonylamino)ethyl]benzoic acid (10-S1). To a solution of 10 (2.47 g, 12.2

mmol) in THF (80 mL) and 1.0 M aq. NaOH (35 mL) was added benzylchloroformate (2.51 g, 14.7 mmol) dropwise at 0 °C. After being stirred for 1 h at room temperature, the volatile part was removed in vacuo. The aqueous solution was washed with EtOAc, acidified to pH 4, and the precipitate was filtered. The solid was washed twice with 0.5 N aq. HCl solution (20 mL) and dried under high vacuum for overnight. Purity of the product was confirmed by TLC analysis and ¹H NMR, and the product was used for the next reaction without further purification. White solid was obtained (2.63 g, 72%). $R_f = 0.45$ (100% EtOAc); ¹H NMR (500 MHz, DMSO-d6) δ 12.79 (br s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.88 - 7.90 (m, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.31 - 7.37 (m, 4H), 5.00 (q, J = 12.5 Hz, 2H), 4.74 (m, 1H), 1.35 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, DMSO-d6) δ 167.6, 155.9, 150.6, 137.5, 129.9, 129.7, 128.8, 128.3, 126.4, 65.8, 50.5, 23.0 (two aromatic peaks are overlapped).

(*S*)-*tert*-butyl 4-[1-(benzyloxycarbonylamino)ethyl]benzoate (10-S2). To a solution of 10-S1 (2.35 g, 7.85 mmol) in anhydrous CH₂Cl₂ (50 mL) was added concentrated sulfuric acid (0.3 mL). The solution was saturated with isobutylene at -78 °C, causing a volume increase of 30 mL. After stirring in a pressure tube for 7 days at room temperature, the suspension was changed to a clear solution, and the reaction was stopped. To this solution was added 5% aq. NaHCO₃ (50 mL), and the aqueous phase was extracted twice with CH₂Cl₂ (50 mL). The combined organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by short silica gel plug to afford 10-S2 (2.46 g, 88%) as a transparent oil. $R_f = 0.5$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.93 (d, J = 8.0 Hz, 2H), 7.32 (br s, 7H), 5.01 – 5.10 (m, 3H), 4.87 (s, 1H), 1.57 (s, 9H), 1.44 (d, J = 8.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 165.6, 155.8, 148.7, 136.6, 130.9, 129.8, 129.8, 128.5, 128.1, 125.8, 80.9, 66.7, 60.4, 50.6, 28.2, 22.4; MS (ESI, CH₃CN) [2M+Na⁺] = 734.2.

(*S*)-*tert*-butyl 4-(1-aminoethyl)benzoate (11). Compound 10-S2 (0.65 g, 1.84 mmol) was dissolved in a mixture of MeOH/H₂O/AcOH (7:2:1, 20 mL) and subjected to catalytic hydrogenation on 5% Pd/C (50 mg) at 1 atm. After stirring for 1.5 h, the reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. Acetic acid was removed by an extraction with a 5% aq. NaHCO₃ solution to provide free amine 11 as a white powder (0.40 g, 99%). $R_f = 0.2$ (EtOAc/MeOH = 1 : 1); ¹H NMR (500 MHz, CD₃OD) δ 7.92 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 4.38 (q, J = 6.0 Hz, 1H), 1.50 – 1.52 (m, 12H); ¹³C NMR (125 MHz, CDCl₃) δ 165.1, 143.3, 132.1, 129.9, 126.5, 81.2, 50.7, 28.1, 20.7; MS (ESI, CH₃CN) [M+H⁺] = 221.9

4-[(*S*)-1-((*R*)-tert-butylsulfinamido)ethyl]benzamide (9-S1). Compound 9 (6.63 g, 24.6 mmol) was dissolved in THF (100 mL) at ambient temperature and the solution was cooled down to -10 °C. To this solution, *N*-methylmorpholine (2.98 g, 29.5 mmol) and *iso*-butyl chloroformate (4.03 g, 29.5 mmol) were added successively, and stirring continued for 30 min at -10 °C, and then 29% aqueous ammonia (14 mL) was added. The mixture was stirred at -10 °C for 30 min and at room temperature for overnight. The solution was concentrated to a reduced volume (~30 mL) and partitioned to EtOAc/water (100 mL : 100 mL). Aqueous phase was extracted four times with EtOAc (80 mL), and the combined organic solution was washed with brine, dried over Na₂SO₄, filtered, and evaporated. The residue was recrystallized in EtOH/ether or in MeOH/DMF/ether to afford **9-S1** (6.23 g, 94%) as a yellowish solid. $R_f = 0.15$ (100% EtOAc); ¹H NMR (500 MHz, DMSO-*d*6) δ 7.92 (s, 1H), 7.83 (d, *J* = 8.0 Hz, 2H), 7.42 (d, *J* = 8.5 Hz, 2H), 7.31 (s, 1H), 5.42 (d, *J* = 5.0 Hz, 1H), 4.46 (m, 1H), 1.47 (d, *J* = 7.0 Hz, 3H), 1.11 (s, 9H); ¹³C NMR (125 MHz, DMSO-*d*6) δ 168.2, 148.6, 133.4, 127.9, 126.9,

55.5, 55.1, 25.2, 23.1;MS (ESI, CH_3CN) [M+H⁺] = 269.5.

(S)-4-(1-aminoethyl)benzamide hydrochloride (12·HCl). To an ice-cold solution of 9-S1 (3.96 g, 14.7 mmol) in MeOH (30 mL) was slowly added 4 M HCl in 1,4-dioxane solution (60 mL). The mixture was stirred at room temperature for 2.5 h. The volume of the reaction mixture was reduced by evaporation, and diethyl ether was added to precipitate the product. The white precipitate was then filtered and washed thoroughly with ether (50 mL) three times to provide 12·HCl (2.93 g, 99%) as a white solid.

$$H_2N$$
 NH_2
 NH_2

(*S*)-4-(1-aminoethyl)benzamide (12). To an ice-cold solution of 9-S1 (3.96 g, 14.7 mmol) in MeOH (30 mL) was slowly added 4 M HCl in 1,4-dioxane solution (60 mL). The mixture was stirred at room temperature for 2.5 h. The volume of the reaction mixture was reduced by evaporation, and diethyl ether was added to precipitate the product. The white precipitate was then filtered and washed thoroughly with ether (50 mL) three times to provide an HCl salt form of 12 (2.93 g, 99%) as a white solid. HCl salt form of 12: 1 H NMR (500 MHz, D₂O) δ 7.69 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 4.58 (q, J = 7.0 Hz, 1H), 1.62 (d, J = 7.0 Hz, 3H); 13 C NMR (125 MHz, D₂O) δ 171.6, 141.8, 132.9, 128.3, 126.9, 50.7, 19.4. Free amine 12 was obtained after dissolving the salt in small amount of 5% aq. NaHCO₃ solution and extraction with EtOAc several times. The organic solution was dried over Na₂SO₄ and concentrated in vacuo to provide a yellowish solid. 1 H NMR (500 MHz, D₂O) δ 7.67 – 7.70 (m, 2H), 7.37 – 7.40 (m, 2H), 4.02 (q, J = 7.0 Hz, 1H), 1.27 (d, J = 7.0 Hz, 3H); 13 C NMR (125 MHz, D₂O) δ 172.7, 151.5, 131.0, 127.8, 126.1, 50.0, 23.8; MS (ESI, CH₃OH) [2M+H⁺] = 329.1, [3M+H⁺] = 493.2.

3. Synthesis of Guanidine-Functionalized Nspe Derivative.

S13-5 (*N*spe-guanidine) was synthesized starting from commercially available (*S*)-α-methyl-4-nitrobenzylamine hydrochloride (Scheme S1). The amino group was protected by the treatment of ethyl trifluoroacetate under basic conditions. Reduction of nitro group employing a catalytic hydrogenation provided aromatic amine **S13-3**. Guanidination of **S13-3** using 1,3-bis(*tert*-butoxycarbonyl)-2-methyl-2-thiopseudourea in the presence of mercury (II) chloride provided **S13-4** in a 90% yield. Deprotection of trifluoroacetamide afforded **S13-5**.

Scheme S1. Synthesis of **S13-5** (*N*spe-guanidine).

$$CH_3$$
 H_2N
 H_2N

Reagents and conditions: (a) Ethyl trifluoroacetate, Et₃N, CH₂Cl₂, 89%; (b) H₂, Pd/C, MeOH, quant.; (c) 1,3-Bis(*tert*-butoxycarbonyl)-2-methylthiopseudourea, HgCl₂, Et₃N, DMF, 90%; (d) LiOH (aq.), MeOH, 74%.

$$F_3C$$
 N
 N
 NO_2

(S)-N-[1-(4-nitrophenyl)ethyl]trifuloroacetamide (S13-2). To a stirred ice-cold solution of (S)-α-methyl-4-nitrobenzylamine hydrochloride (S13-1, 10.3 g, 50.8 mmol) in anhydrous CH_2Cl_2 (250 mL) was added ethyl trifluoroacetate (21.7 g, 152.5 mmol) followed by triethylamine (15.3 g, 152.5 mmol). The reaction mixture was stirred under nitrogen at room temperature for 5 days, and the solution was concentrated in vacuo. The residue was dissolved in EtOAc (250 mL), washed with 1.0N HCl (2 × 50 mL), 5% NaHCO₃ (2 × 50 mL), and brine (100 mL), and dried over Na₂SO₄. After evaporation of the organic solvent, the purity of the product was confirmed by 1 H NMR, and the compound was used for

next reaction without further purification. A white crystalline solid was obtained (11.8 g, 89%). $R_f = 0.3$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 8.19 – 8.21 (m, 2H), 7.45 – 7.48 (m, 2H), 6.75 (s, 1H), 5.18 (m, 1H), 1.60 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 148.3, 147.6, 127.1, 124.2, 116.8, 114.5, 49.4, 21.3.

(*S*)-*N*-[1-(4-aminophenyl)ethyl]trifuloroacetamide (S13-3). Compound S13-2 (13.0 g, 49.6 mmol) was dissolved in MeOH (100 mL) and subjected to catalytic hydrogenation on Pd/C (5 wt.%, 200 mg) at 1 atm. After the 2 days stirring at room temperature, the reaction was completed according to the TLC. The reaction mixture was filtered through Celite, and the filtrate was concentrated in vacuo. The residue was purified by short silica gel plug to afford S13-3 (11.4 g, 99%) as a reddish solid. $R_f = 0.1$ (hexane/EtOAc = 3 : 1); ¹H NMR (500 MHz, CDCl₃) δ 7.07 – 7.10 (m, 2H), 6.63 – 6.65 (m, 2H), 6.54 (s, 1H), 5.02 (m, 1H), 3.70 (br s, 2H), 1.52 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 146.4, 130.6, 127.5, 117.0, 115.3, 114.7, 49.4, 20.7; MS (ESI, CH₃CN) [M+H⁺] = 233.0.

(S)-N-{1-[4-(N,N'-bis(tert-butoxycarbonyl)guanidino)phenyl]ethyl}trifuloroacetamide (S13-4). To a solution of S13-3 (5.91 g, 25.5 mmol) in anhydrous DMF (150 mL) was added 1,3-bis(tert-butylcarbonyl)-2-methylthiopseudourea (11.09 g, 38.2 mmol), triethylamine (10.3 g, 101.8 mmol), and mercury(II) chloride (10 g, 36.8 mmol). The suspension was kept stirring at room temperature for overnight. The reaction mixture was diluted with CH_2Cl_2 , washed with Na_2CO_3 solution, and filtered through a pad of Celite. The organic layer was washed with water and brine, dried over Na_2SO_4 , and then concentrated in vacuo. The residue was purified by flash column chromatography (hexane/EtOAc = 10 : 1, $R_f = 0.3$), to give S13-4 (10.8 g, 90%) as a white foamy solid. $R_f = 0.65$

(hexane/EtOAc = 3 : 1); 1 H NMR (500 MHz, CDCl₃) δ 11.57 (s, 1H), 10.28 (s, 1H), 7.52 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5 Hz, 2H), 6.91 (br s, 1H), 5.03 (m, 1H), 1.43 - 1.50 (m, 21 H); 13 C NMR (125 MHz, CDCl₃) δ 163.4, 156.5, 153.6, 153.3, 137.3, 136.5, 126.8, 122.8, 117.0, 83.9, 79.8, 49.3, 28.1, 28.0, 20.7; MS (ESI, CH₃CN) [M+H⁺] = 474.9.

(*S*)-1-{4-[*N*,*N*'-bis(tert-butoxycarbonyl)guanidino]phenyl}ethylamine (S13-5). To a stirred ice-cold solution of S13-4 (5.34 g, 11.3 mmol) in MeOH (80 mL) and THF (100 mL) under nitrogen was added 2.0 M aq. LiOH (50 mL) dropwise, and the mixture was stirred at room temperature for 3 h. After evaporation of organic solvents under reduced pressure, the aqueous solution was extracted three times with EtOAc (100 mL). The combined organic extract was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by flash column chromatography (CH₂Cl₂/MeOH/Et₃N = 15 : 1 : 0.1, R_f = 0.35), to give S13-5 (3.16 g, 74%) as a white foamy solid. ¹H NMR (500 MHz, CDCl₃) δ 11.61 (s, 1H), 10.26 (s, 1H), 7.48 – 7.52 (m, 2H), 7.26 – 7.28 (m, 2H), 4.07 (q, J = 6.5 Hz, 1H), 2.25 (br s, 2H), 1.51 (s, 9H), 1.47 (s, 9H), 1.35 (d, J = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 163.6, 153.7, 153.3, 143.4, 135.5, 126.3, 122.6, 83.7, 79.6, 50.9, 28.2, 28.1, 25.1; MS (ESI, CH₃CN) [M+H⁺] = 378.9.

4. Sidechain cleavage in strong acidic conditions:

A (S)-N-(1-Phenylethyl)glycine (Nspe) derivative with electron-donating substituent at the para-position can undergo sidechain cleavage in strong acidic conditions (i.e. cleavage from resin using 95% TFA for 10 minutes). Proposed cleavage mechanism is shown in Scheme S2. Model peptoid containing Nspe-guanidine underwent the sidechain cleavage (Figure S1).

Scheme S2. Proposed cleavage mechanism.

Figure S1. Observed example of the sidechain cleavage.

5. Synthesis of peptoid 20.

Scheme S3. Synthesis of 20.




Figure S2. LC-MS data of crude 20-S1.




Figure S3. Analytical HPLC spectrum of crude **20-S1**. Vydac C18 column was used at a flow rate of 1 mL/min at 60 °C. The mobile phase was used as follows: (A, water + 0.1% TFA; B, CH₃CN + 0.1% TFA) a gradient starting with 20% B to 70% B over 35 min, a gradient to 95% B over 5 min, and then a gradient to 20% B over 5 min. UV detection was at 220 nm.




Figure S4. LC-MS data of crude 20. Trityl and peptoid peaks are overlapped.





Figure S5. MALDI-TOF mass spectrometry data of purified 20.

6. Synthesis of homodimeric peptoid helix bundle 21.

Peptoid 20 (13 mg, 11 μ mol) was dissolved in MeOH (1 mL). The reaction flask containing the solution was open to air, and the stirring continued for 2 days at room temperature. The reaction mixture was directly used for MS and analytical HPLC analyses, and purified by preparative HPLC.



Scheme S4. Synthesis of 21.




Figure S6. Analytical HPLC chromatogram of thiol peptoid **20** and peptoid disulfide **21**. Vydac C18 column was used at a flow rate of 1 mL/min at 60 °C. The mobile phase was used as follows: (A, water + 0.1% TFA; B, CH₃CN + 0.1% TFA) a gradient starting with 20% B to 100% B over 25 min, 5 min using 100% B, and then a gradient to 20% B over 15 min. UV detection was at 220 nm.






Figure S7. MALDI-TOF mass spectrometry data of purified 21.

7. HPLC and ESI-mass data of peptoids 13-19.


13:




14:




15:




16:




17:



18:



19:




HPLC conditions for peptoid 13-19:


Waters analytical HPLC system (2695 Separations Module, 2998 detector) was used. Phenomenex Jupiter C18 column (250 x 2.00 mm) was used at a flow rate of 0.2 mL/min at 55 $^{\circ}$ C. The mobile phase was used as follows: (A, water + 0.1% TFA; B, CH₃CN + 0.1% TFA) a gradient starting with 1% B to 99% B over 40 min and a gradient to 1% B over 5 min. UV detection was at 220 nm.


peptoids	mass calculated	mass observed
13	1144.61	1146.65 (H ⁺)
14	1187.62	1189.90 (H ⁺)
15	1230.63	1231.70 (H ⁺)
16	1230.63	1232.18 (H ⁺)
17	1316.64	1317.92 (H ⁺)
18	1445.66	1447.36 (H ⁺)
19	1232.59	1233.50 (H ⁺)


Table S1. ESI-MS data of peptoids 13 - 19.


8. ¹H and ¹³C NMR spectra.






























































ppm

F2 - Processing parameters
SI 32768
SP 125.7577890 MH2
MDW EM
SSB 0
LB 1.00 H2
GB 0.9FC 1.40

